New drug sales help boost Novartis Q1 profit (Update)

April 24, 2014 by John Heilprin
The Aug. 12, 2005 file photo shows the logo of Swiss company Novartis in Basel, Switzerland. Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday, April 22, 2014 with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally. (AP Photo/Keystone, Steffen Schmidt)

Strong new drug sales and higher operating income helped Swiss pharmaceutical firm Novartis AG report a 24 percent rise in first-quarter profit.

The company said Thursday that its net profit of nearly $2.97 billion, up from $2.42 billion in the same period last year, was helped by sales growth from some of its newest product launches, such as Gilenya for multiple sclerosis and Afinitor for cancer, and higher operating income.

The company based in Basel, Switzerland, has been counting on these new drugs to offset patent expirations, such as its blockbuster heart drug Diovan which lost U.S. protection in 2012.

Also helping was a $900 million pretax gain from selling part of its diagnostics business to the Spanish health care company Grifols SA for $1.68 billion in November.

The company noted that the strong new drug sales were reinforced by asthma treatment Xolair gaining approval in the European Union and United States and meningitis B vaccine Bexsero being recommended in the U.K. and gaining new designation in the U.S. Growth in emerging markets, particularly China, also helped.

"Novartis delivered a solid quarter, with all divisions contributing to growth," CEO Joseph Jimenez said.

The Jan. 29, 2014 file photo shows Novartis CEO Joseph Jimenez as he arrives for the annual balance press conference in Basel, Switzerland. Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday, April 22, 2014 with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally. (AP Photo/Keystone, Steffen Schmidt)

But the company's overall sales rose only 1 percent, to $14.02 billion, in large part due to pressure that some of its drugs, such as Afinitor for cancer and Glivec for leukemia, face from competition by generic suppliers.

Jimenez emphasized that the major overhaul of its business that Novartis launched Tuesday—a series of "transformational" multibillion-dollar deals with Britain's GlaxoSmithKline PLC and Eli Lilly & Co. of the United States—would "position the company for future success based on our sharpened focus, innovation power and financial strength."

Novartis shares dropped 1.9 percent to close at 74.80 Swiss francs Thursday, after rising by 3 percent in the wake of Tuesday's announcement.

Explore further: Novartis Q4 net profit rises to $2.0 billion

Related Stories

Novartis Q4 net profit rises to $2.0 billion

January 29, 2014
Swiss drug maker Novartis AG reported a 2 percent rise in fourth-quarter net profit Wednesday, helped by delays in generic competition to its blockbuster drugs.

Novartis reshapes business with GSK, Lilly deals (Update)

April 22, 2014
Swiss pharmaceutical firm Novartis AG launched a major overhaul of its business Tuesday, unveiling a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.'s Eli Lilly & Co. that heralds more ...

Eli Lilly to buy part of Novartis for $5.4 bn

April 22, 2014
US pharmaceutical giant Eli Lilly said Tuesday it has reached an agreement to acquire the animal health division of Novartis of Switzerland for $5.4 billion (3.9 billion euros).

Swiss pharma Novartis ups full-year sales outlook (Update)

October 22, 2013
Swiss pharmaceutical giant Novartis AG raised its full-year sales outlook because of delays in generic competition to its blockbuster blood pressure drug Diovan, even though it said negative currency trends contributed to ...

Novartis posts profit gain thanks to new drugs (Update)

April 24, 2013
(AP)—Swiss pharmaceutical company Novartis AG reported a 6.7 percent increase in profit for the first quarter Wednesday, boosted by new products and emerging markets.

Recommended for you

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

Best of Last Year – The top Medical Xpress articles of 2016

December 23, 2016
(Medical Xpress)—It was a big year for research involving overall health issues, starting with a team led by researchers at the UNC School of Medicine and the National Institutes of Health who unearthed more evidence that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.